• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real-world evidence study.

作者信息

Schwensen J F B, Nielsen V W, Nissen C V, Sand C, Gniadecki R, Thomsen S F

机构信息

Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark.

Division of Dermatology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.

出版信息

J Eur Acad Dermatol Venereol. 2021 May;35(5):e341-e343. doi: 10.1111/jdv.17092. Epub 2021 Jan 10.

DOI:10.1111/jdv.17092
PMID:33338282
Abstract
摘要

相似文献

1
Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real-world evidence study.古塞库单抗在50例既往接受过其他生物制剂治疗的中度至重度斑块状银屑病患者中的有效性和安全性：一项回顾性真实世界证据研究。
J Eur Acad Dermatol Venereol. 2021 May;35(5):e341-e343. doi: 10.1111/jdv.17092. Epub 2021 Jan 10.
2
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.在真实环境中，古塞库单抗治疗银屑病的疗效和安全性：西班牙银屑病组的一项回顾性、观察性、多中心研究。
Dermatol Ther. 2022 Feb;35(2):e15231. doi: 10.1111/dth.15231. Epub 2022 Jan 17.
3
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.中度至重度斑块状银屑病患者中，ixekizumab与guselkumab的头对头比较：一项随机双盲试验的12周疗效、安全性及反应速度
Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15.
4
Long-Term Single Center Experience in Treating Plaque Psoriasis With Guselkumab.古塞单抗治疗斑块状银屑病的长期单中心经验。
J Cutan Med Surg. 2020 Nov/Dec;24(6):588-595. doi: 10.1177/1203475420932514. Epub 2020 Jun 8.
5
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis.古塞库单抗：一种抗白细胞介素-23 抗体，用于治疗中重度斑块状银屑病。
Eur J Dermatol. 2021 Feb 1;31(1):3-16. doi: 10.1684/ejd.2021.3965.
6
Real-life experience of guselkumab in patients with psoriasis.古塞库单抗治疗银屑病患者的真实生活经验。
Dermatol Ther. 2020 Nov;33(6):e13964. doi: 10.1111/dth.13964. Epub 2020 Jul 14.
7
Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis.评估古塞库单抗：一种用于治疗斑块状银屑病的抗白细胞介素-23抗体。
Drug Des Devel Ther. 2019 Jun 18;13:1993-2000. doi: 10.2147/DDDT.S137588. eCollection 2019.
8
Guselkumab for the treatment of moderate-to-severe plaque psoriasis.古塞库单抗用于治疗中度至重度斑块状银屑病。
Expert Rev Clin Pharmacol. 2018 Apr;11(4):333-344. doi: 10.1080/17512433.2018.1445967. Epub 2018 Mar 6.
9
Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group.在真实临床环境中，古塞库单抗治疗中度至重度斑块状银屑病52周的疗效：西班牙银屑病研究组的观察性、回顾性、多中心研究
J Dermatolog Treat. 2022 Sep;33(6):2878-2880. doi: 10.1080/09546634.2022.2079596. Epub 2022 May 26.
10
Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: A real-life 52-week retrospective study.古塞单抗治疗失败的银屑病患者的疗效和安全性：一项真实世界的 52 周回顾性研究。
Dermatol Ther. 2021 Jan;34(1):e14673. doi: 10.1111/dth.14673. Epub 2020 Dec 19.

引用本文的文献

1
Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data.抗白细胞介素 23 生物制剂治疗银屑病：真实世界经验与临床试验数据对比。
Immunol Res. 2023 Jun;71(3):328-355. doi: 10.1007/s12026-022-09356-y. Epub 2023 Jan 4.
2
Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis.真实世界数据显示，古塞库单抗治疗斑块状银屑病患者的药物生存期较长。
Acta Derm Venereol. 2022 Aug 11;102:adv00755. doi: 10.2340/actadv.v102.685.
3
Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study.
古塞库单抗在提高应答率方面具有高疗效和维持性，直至第 48 周：一项真实世界研究。
Dermatol Ther. 2022 Oct;35(10):e15670. doi: 10.1111/dth.15670. Epub 2022 Aug 8.
4
Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis. Guselkumab 治疗斑块状银屑病患者的全国真实世界队列的治疗结局和持久性。
Acta Derm Venereol. 2022 Jan 18;102:adv00631. doi: 10.2340/actadv.v101.910.